A First Case of Hepatic Angiosarcoma Treated with Recombinant Interleukin-2

Mitsui Fukiko

Aikata Hiroshi

Hashimoto Yoshimasa

Nagaoki Yuko

Kimura Yuki

Katamura Yoshio

Kawaoka Tomokazu

Takaki Shintaro

Hiraga Nobuhiko

Tsuge Masataka

Waki Koji

Hiramatsu Akira

Imamura Michio

Kawakami Yoshiiku

Takahashi Shoichi

Arihiro Koji

Chayama Kazuaki

Hiroshima Journal of Medical Sciences

[PISSN] 0018-2052

[EISSN] 2433-7668

[NCID] AA00664312

A 60 year-old woman was admitted to our hospital because of management of multiple liver tumors. According to image findings and liver biopsy, she was diagnosed as having epithelioid hemangioendothelioma of the liver accompanied by metastases in the spleen, lungs and bones. Based on the spread of the liver tumors and the extensive systemic metastases, she was considered inoperable. Instead, she received hepatic arterial infusion therapy using recombinant interleukin-2. However, she died due to liver failure about two months after admission. Autopsy revealed that the liver tumor was angiosarcoma. It is difficult to differentiate angiosarcoma from epithelioid hemangioendothelioma based on the image findings and pathological findings of percutaneous liver biopsy. Many cases are diagnosed as angiosarcoma at autopsy. There is no established effective treatment for hepatic angiosarcoma, because the tumor stage at the time of diagnosis is often progressive. To date, immunotherapy with recombinant interleukin-2 has been reported to be effective clinically for cutaneous angiosarcoma, such as of the scalp and facial skin. To our knowledge, there have been no reported cases of hepatic angiosarcoma treated with recombinant interleukin-2. Our case is important should recombinant interleukin-2 be considered effective for hepatic angiosarcoma in the future.

Hepatic angiosarcoma

Recombinant interleukin-2

Hepatic arterial infusion therapy

Medical sciences [ 490 ]

eng

Hiroshima University Medical Press

(c) Hiroshima University Medical Press.

[ISSN] 0018-2052

[NCID] AA00664312